indirubin-3'-monoxime has been researched along with bortezomib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cheng, X; Christ, J; Eisenbrand, G; Merz, KH; Muehlbeyer, S; Thommet, A; Vatter, S; Wölfl, S; Zeller, J | 1 |
| An, G; Anderson, KC; Cheng, T; Fang, T; Hao, M; He, Y; Huang, C; Huang, W; Li, Y; Liu, L; Meng, F; Qiu, L; Sui, W; Sun, H; Wang, K; Wang, L; Wei, X; Yu, T; Yu, Z; Zhao, Y | 1 |
3 other study(ies) available for indirubin-3'-monoxime and bortezomib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Indoles; Oximes; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Solubility; Structure-Activity Relationship | 2017 |
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Multiple Myeloma; NF-kappa B; NIMA-Related Kinases; Oximes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Ubiquitin-Specific Peptidase 7 | 2022 |